Use of EDG receptor binding agents in cancer

Details for Australian Patent Application No. 2011205049 (hide)

Owner Novartis AG

Inventors Mechtcheriakova, Diana; Wood, Jeanette Marjorie; Brinkmann, Volker; Lassota, Peter T.; Baumruker, Thomas; La Montagne, Kenneth Richard

Agent Davies Collison Cave

Pub. Number AU-A-2011205049

Parent 2007237378

Filing date 28 July 2011

Wipo publication date 18 August 2011

International Classifications

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61K 31/135 (2006.01) - having aromatic rings, e.g. methadone

A61K 31/137 (2006.01) - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine

A61K 31/381 (2006.01) - having five-membered rings

A61K 31/661 (2006.01) - Phosphorus acids or esters thereof not having PC bonds, e.g. fosfosal, dichlorvos, malathion

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 35/00 (2006.01) Antineoplastic agents

A61P 35/04 (2006.01) Antineoplastic agents

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

Event Publications

11 August 2011 Complete Application Filed

18 August 2011 Application Open to Public Inspection

  Published as AU-A-2011205049

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011205050-Solid pharmaceutical compositions comprising a S1P recpetor agonist and a sugar alcohol

2011205048-Compounds and methods for the treatment or prevention of flavivirus infections